Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Market Cap	$6.48M	P/E Ratio	N/A
52W High	$37.50	52W Low	$3.10
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	79.6%	52W Position	0.3%
Overall Score	36	Value Score	40
Quality Score	--	Technical Score	33

EPS Current Est	$-18.46	EPS Next Est	$-6.64
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LYRA	$3.22	+2.88%	38.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LYRA	$3.22	+2.9%	38.99K
3
4
5
6

LYRA

LYRA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Lyra Therapeutics Inc. Data in Excel

Get Lyra Therapeutics Inc. Data in Excel